Form 8-K - Current report:
SEC Accession No. 0001193125-23-069219
Filing Date
2023-03-13
Accepted
2023-03-13 17:26:56
Documents
12
Period of Report
2023-03-13
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d475007d8k.htm   iXBRL 8-K 24672
  Complete submission text file 0001193125-23-069219.txt   149819

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ikt-20230313.xsd EX-101.SCH 2824
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ikt-20230313_lab.xml EX-101.LAB 18738
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ikt-20230313_pre.xml EX-101.PRE 11691
6 EXTRACTED XBRL INSTANCE DOCUMENT d475007d8k_htm.xml XML 3469
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39676 | Film No.: 23728308
SIC: 2836 Biological Products, (No Diagnostic Substances)